Literature DB >> 15209629

Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma.

Katsuhisa Omagari1, Sumihisa Honda, Yoshiko Kadokawa, Hajime Isomoto, Fuminao Takeshima, Kenji Hayashida, Yohei Mizuta, Ikuo Murata, Shigeru Kohno.   

Abstract

BACKGROUND: The long-term prognosis of hepatocellular carcinoma (HCC) remains poor and the prediction of survival is often difficult because of the limited liver function and frequent recurrence of HCC in most patients. Therefore, a prognostic classification of HCC should account for both tumor-related variables and liver function.
METHODS: The value of reported prognostic factors for HCC was assessed and a new prognostic classification was established called the 'SLiDe' scoring system (S, stage; Li, liver damage; De, des-gamma-carboxy prothrombin) using 'stage' and 'liver damage' of the recently revised 4th edition of the Japanese staging system edited by the Liver Cancer Study Group of Japan, and the serum level of des-gamma-carboxy prothrombin (DCP) in 177 patients with HCC.
RESULTS: Univariate analysis identified Child-Pugh stage, liver damage, tumor morphology, portal vein thrombosis, stage, serum level of alpha-fetoprotein (AFP), serum level of DCP, and initial treatment as significant prognostic factors. Of these, liver damage, stage, and serum level of DCP remained independent predictive factors of survival after multivariate prognostic analysis using the proportional hazards regression model. Therefore, a new prognostic scoring system (SLiDe scoring system) was derived that assigned a linear score (0/1/2/3) to these three covariates. This SLiDe scoring system was statistically a better model for predicting outcome in the present study population than the Cancer of the Liver Italian Program (CLIP) and the Japan Integrated Staging (JIS) scoring systems, as judged by the Akaike Information Criteria.
CONCLUSION: The SLiDe scoring system is useful for the assessment of the prognosis of patients with HCC as long as the Japanese staging system is used, although this uses parameters such as the indocyanine green retention test and DCP, which are not examined routinely in every part of the world. Therefore, the proposed classification should be further validated in other large study populations. Copyright 2004 Blackwell Publishing Asia Pty Ltd

Entities:  

Mesh:

Year:  2004        PMID: 15209629     DOI: 10.1111/j.1440-1746.2004.03350.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  12 in total

1.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Authors:  Al B Benson; Thomas A Abrams; Edgar Ben-Josef; P Mark Bloomston; Jean F Botha; Bryan M Clary; Anne Covey; Steven A Curley; Michael I D'Angelica; Rene Davila; William D Ensminger; John F Gibbs; Daniel Laheru; Mokenge P Malafa; Jorge Marrero; Steven G Meranze; Sean J Mulvihill; James O Park; James A Posey; Jasgit Sachdev; Riad Salem; Elin R Sigurdson; Constantinos Sofocleous; Jean-Nicolas Vauthey; Alan P Venook; Laura Williams Goff; Yun Yen; Andrew X Zhu
Journal:  J Natl Compr Canc Netw       Date:  2009-04       Impact factor: 11.908

Review 2.  Staging systems for hepatocellular carcinoma: Current status and future perspectives.

Authors:  Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Kazuhiko Koike; Hirokazu Nishino; Hisao Tajiri
Journal:  World J Hepatol       Date:  2015-03-27

Review 3.  A discussion of serum albumin level in advanced-stage hepatocellular carcinoma: a medical oncologist's perspective.

Authors:  Ozgur Tanriverdi
Journal:  Med Oncol       Date:  2014-10-15       Impact factor: 3.064

4.  Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report.

Authors:  Pierre-Alain Clavien; Mickael Lesurtel; Patrick M M Bossuyt; Gregory J Gores; Bernard Langer; Arnaud Perrier
Journal:  Lancet Oncol       Date:  2011-10-31       Impact factor: 41.316

5.  Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy.

Authors:  Atsushi Nanashima; Yorihisa Sumida; Takafumi Abo; Hisakazu Shindou; Hidetoshi Fukuoka; Hiroaki Takeshita; Shigekazu Hidaka; Kenji Tanaka; Terumitsu Sawai; Toru Yasutake; Takeshi Nagayasu; Katsuhisa Omagari; Mariko Mine
Journal:  J Gastroenterol       Date:  2006-03       Impact factor: 7.527

6.  Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study.

Authors:  Brian I Carr; Petr Pancoska; Robert A Branch
Journal:  Hepatol Int       Date:  2009-12-24       Impact factor: 6.047

7.  Validation of the 7th edition TNM staging system for hepatocellular carcinoma: an analysis of 8,828 patients in a single medical center.

Authors:  Kwong-Ming Kee; Jing-Houng Wang; Chih-Yun Lin; Chih-Chi Wang; Yu-Fan Cheng; Sheng-Nan Lu
Journal:  Dig Dis Sci       Date:  2013-05-24       Impact factor: 3.199

8.  Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival.

Authors:  Chi-Sin Changchien; Chao-Long Chen; Yi-Hao Yen; Jing-Houng Wang; Tsung-Hui Hu; Chuan-Mo Lee; Chih-Chi Wang; Yu-Fan Cheng; Yu-Jie Huang; Chih-Yun Lin; Sheng-Nan Lu
Journal:  J Gastroenterol       Date:  2008-02-29       Impact factor: 7.527

9.  Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma.

Authors:  Kenichi Hakamada; Norihisa Kimura; Takuya Miura; Hajime Morohashi; Keinosuke Ishido; Masaki Nara; Yoshikazu Toyoki; Shunji Narumi; Mutsuo Sasaki
Journal:  World J Gastroenterol       Date:  2008-03-07       Impact factor: 5.742

Review 10.  Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies.

Authors:  Puneeta Tandon; Guadalupe Garcia-Tsao
Journal:  Liver Int       Date:  2008-12-24       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.